These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The new arms race against melanoma. Lejeune FJ Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449 [No Abstract] [Full Text] [Related]
4. BRAF inhibitors: research accelerates in wake of positive findings. Brower V J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213 [No Abstract] [Full Text] [Related]
5. BRAF in melanoma: current strategies and future directions. Salama AK; Flaherty KT Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823 [TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Alcalá AM; Flaherty KT Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904 [TBL] [Abstract][Full Text] [Related]
9. BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT; McArthur G Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085 [TBL] [Abstract][Full Text] [Related]
10. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Yeh AH; Bohula EA; Macaulay VM Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137 [TBL] [Abstract][Full Text] [Related]
11. Is B-Raf a good therapeutic target for melanoma and other malignancies? Madhunapantula SV; Robertson GP Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288 [TBL] [Abstract][Full Text] [Related]
12. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
13. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
14. Oncogenetics of melanoma: basis for molecular diagnostics and therapy. Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632 [TBL] [Abstract][Full Text] [Related]
15. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579 [TBL] [Abstract][Full Text] [Related]
16. [ASCO highlights in the treatment of metastatic melanoma]. Hertlein A Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933 [No Abstract] [Full Text] [Related]
17. BRAF inhibitors and melanoma. Flaherty KT Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295 [TBL] [Abstract][Full Text] [Related]
18. On or off target: mutations, models, and predictions. Garraway LA; Hahn WC Sci Transl Med; 2010 Jun; 2(35):35ps28. PubMed ID: 20538617 [TBL] [Abstract][Full Text] [Related]
19. The brothers RAF. Kwong LN; Chin L Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832 [TBL] [Abstract][Full Text] [Related]
20. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Rebecca VW; Smalley KS Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427 [No Abstract] [Full Text] [Related] [Next] [New Search]